| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701566 | Journal of Thoracic Oncology | 2017 | 21 Pages |
Abstract
We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jody C. MD, PhD, Henning PhD, Ying MD, PhD, Millie MD, Jane MD, Maximilian MD, PhD, Heather A. MD, Joel W. MD, PhD,